Dihydroetorphine: A potent analgesic: Pharmacology, toxicology, pharmacokinetics, and clinical effects

CNS Drug Reviews

Volumn 8, Issue 4, 2002, Pages 391-404

  Ohmori, Satoshi ^a   Morimoto, Yasunori ^b  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

^b JOSAI UNIVERSITY   (Japan)

Author keywords

Analgesics; Dihydroetorphine; Opioid receptor; Pharmacokinetics; Physical dependence; Tolerance to analgesia; Transdermal patch

Indexed keywords

DIHYDROETORPHINE; FORMALDEHYDE; KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; SIGMA OPIATE RECEPTOR;

BILE; BRAIN; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DEPRESSION; CHINA; CLINICAL TRIAL; CONSTIPATION; DOSE RESPONSE; DRUG DEPENDENCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TOLERANCE; DYSPNEA; FLUSHING; GLUCURONIDATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INJECTION SITE; INTESTINE; LIVER; MICTURITION DISORDER; NAUSEA; NONHUMAN; PAIN; QUALITY OF LIFE; REVIEW; REWARD; RODENT; SIDE EFFECT; SOMNOLENCE; VERTIGO; VOMITING;

EID: 0036961571     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2002.tb00236.x     Document Type: Review

References (79)

1. Aceto MD, Harris LS, Bowman ER. Etorphine: μ-Opioid receptor selective antinociception and low physical dependence capacity. Eur J Pharmacol 1997;338:215-223.
2. Aceto MD, Scates SM, Harris LS, Ji Z. Dihydroetorphine: Physical dependence and stereotypy after continuous infusion in the rat. Eur J Pharmacol 2000;387:31-37.
3. Bayer BM, Daussin S, Hernandez M, Irvin L. Morphine inhibition of lymphocyte production is mediated by an opioid-dependent mechanism. Neuropharmacology 1990;29:369-374.
4. Beardsley PM, Harris LS. Evaluation of the discriminative stimulus and reinforcing effects of dihydroetorphine. Drug Alc Depend 1997;48:77-84.
5. Bentley KW, Hardy DG. Novel analgesics and molecular rearrangements in the morphine-thebaine group. III. Alcohols of the 6,14-endo-ethenotetrahydrooripavine series and derived analogs of N-allylnormorphine and -norcodeine. J Am Chem Soc 1967;89:3281-3292.
6. Cao YX, Sun YL, Xing F, Wang NY, Gao WX. A survey of 185 dihydroetorphine hydrochloride abusers. Chin Bull Drug Depend 1995;4:21-24.
7. Chen XP, Guo QD, Shi TS. Studies on transdermal delivery system of dihydroetorphine hydrochloride. Acta Pharmacol Sinica 1996;31:770-774.
8. Chen MH, Li QS, Shen Y, Ma HJ, Zuo XJ. Decrease of cAMP and increase of amino acids contents in mouse brain after dihydroetorphine tolerance. Acta Pharmacol Sinica 1998;19:91-93.
9. Chen YN, Yang YH, Liu YH, Jiao XL, Xiao YP, Ai M. A survey on and analysis of dihydroetorphine utilization. Chin Bull Drug Depend 1995;4:16-20.
10. Choe CH, Smith FL. Sedative tolerance accompanies tolerance to the analgesic effects of fentanyl in infant rats. Pediatr Res 2000;47:727-735.
11. Duttaroy A, Yoburn BC. The effect of intrinsic efficacy on opioid tolerance. Anesthesiology 1995;82: 1226-1236.
12. Foley KM. Opioid analgesics in clinical pain management. In: Herz A, Ed. Handbook of experimental pharmacology. Vol. 104/11. Opioids II. Berlin: Springer-Verlag, 1993;697-743.
13. Guo QD, Chen XP, Shi TS. Effect of vehicle pH, drug concentration and azone on the snake skin permeation of dihydroetorphine hydrochloride. Chin Pharm J 1997;32:349-352.
14. Huang M, Qin BY. Analgesic and other central nervous system depressive effects of dihydroetorphine. Acta Pharmacol Sinica 1982;3:9-13.
15. Huang M, Qin BY. Physical dependence of dihydroetorphine in mice and monkeys. Acta Pharmacol Sinica 1982;3:81-84.
16. Huang M, Wang MY, Yuan SL, Qin BY. Pharmacodynamics and pharmacokinetics of dihydroetorphine hydrochloride administered sublingually in mice and rats. Acta Pharmacol Sinica 1988;9:308-312.
17. Jasinski DR, Griffith JD, Carr CB. Etorphine in man: 1. Subjective effects and suppression of morphine abstinence. Clin Pharmacol Ther 1975; 17:267-272.
18. Kamei J, Iwamoto Y, Suzuki T, Misawa M, Nagase H, Kasuya Y. Antitussive effect of dihydroetorphine in mice. Eur J Pharmacol 1994;260:257-259.
19. Kamei J, Suzuki T, Nagase H. Agonist and antagonist properties of dihydroetorphine for μ-opioid receptors in mice. Neurosci Lett 1996;215:87-90.
20. Kamei J, Suzuki T, Misawa M, Nagase H, Kasuya Y. Antinociceptive effect of dihydroetorphine in diabetic mice. Eur J Pharmacol 1995;275:109-113.
21. Katsumata S, Minami M, Nakagawa T, Iwamura T, Satoh M. Pharmacological study of dihydroetorphine in cloned μ-,δ- and κ-opioid receptors. Eur J Pharmacol 1995;291:367-373.
22. Keith DE, Anton B, Murray SR, et al. μ-Opioid receptor internalization: Opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol Pharmacol 1998;53: 377-384.
23. Lee KO, Akil H, Woods JH, Traynor JR. Differential binding properties of oripavines at cloned μ- and δ-opioid receptors. Eur J Pharmacol 1999;378:323-330.
24. Li YS, Li JL, Qu FL. Using dihydroetorphine to control cancer pain. Chin J New Drug 1996;5:122-123.
25. Liu ZM, Cao JQ, Shi F, Cai ZJ. An epidemiological study on dihydroetorphine abuse. Chin Bull Drug Depend 1995;4:223-231.
26. Liu JG, Gong ZH, Qin BY. Effects of low-pH treatment on cAMP second messenger system regulated by different opioid agonists. Acta Pharmacol Sinica 1999;20:500-504.
27. Liu F, Luo Y, Feng JL, Hu XY. Determination of dihydroetorphine in biological fluids by gas chromatography-mass spectrometry using selected-ion monitoring. J Chromatogr B 1996;679:113-118.
28. Liu ZH, Zhang KG. Dihydroetorphine-induced place preference was mediated by dopamine D1 receptors in rats. Acta Pharmacol Sinica 1999;20:381-384.
29. Liu ZH, Zhang KG. Dihydroetorphine reinforcement studied by conditioned place preference in rats. Chin J Drug Depend 1999;8:27-29.
30. Luo Y, Feng JL, Liu F, Hu XY. Identification of dihydroetorphine in biological fluids by gas chromatography-mass spectrometry. J Chromatogr B 1995;667:344-348.
31. Lysle DT, Coussons ME, Watts VJ, Bennett EH, Dykstra LA. Morphine-induced alterations of immune status: Dose-dependency, compartment specificity and antagonism by naltrexone. J Pharmacol Exp Ther 1993;265:1071-1078.
32. Martin TJ, Hairston CT, Lutz PO, Harris LS, Porreca F. Anti-allodynic actions of intravenous opioids in the nerve injured rat: Potential utility of heroin and dihydroetorphine against neuropathic pain. Eur J Pharmacol 1998;357:25-32.
33. Martin TJ, Kim SA, Harris LS, Smith JE. Potent reinforcing effects of dihydroetorphine in rats. Eur J Pharmacol 1997;324:141-145.
34. McCormack K, Prather P, Chapleo C. Some new insights into the effects of opioids in phasic and tonic nociceptive tests. Pain 1998;78:79-98.
35. Nichols ML, Bian D, Ossipov MH, Lai J, Porreca F. Regulation of opioid antiallodynic efficacy by cholecystokinin in a model of neuropathic pain in rats. J Pharmacol Exp Ther 1995;275:1339-1345.
36. Niwa M, Al-Essa LY, Ohta S, et al. Opioid receptor interaction and adenylyl cyclase inhibition of dihydroetorphine: Direct comparison with etorphine. Life Sci 1995;56:PL395-400.
37. Ohmori S, Fang L, Kawase M, Saito S, Morimoto Y. Tolerance to analgesia and dependence liability by topical application of dihydroetorphine. Eur J Pharmcol 2001;423:157-166.
38. Ohmori S, Hayashi T, Kawase M, Saito S, Morimoto Y. Quantitative determination of dihydroetorphine in rat plasma and brain by liquid chromatography-tandem mass spectrometry. J Chromatogr B 2000;740: 253-263.
39. Ohmori S, Hayashi T, Kawase M, Saito S, Morimoto Y. Pharmacokinetic and pharmacodynamic evaluations of a potent analgesic dihydroetorphine in hairless rats. J Pharmacol Exp Ther 2001;296:528-536.
40. Ohmori S, Hayashi T, Kawase M, Saito S, Sugibayashi K, Morimoto Y. Transdermal delivery of a potent analgesic dihydroetorphine: Kinetic analysis of skin permeation and analgesic effect in the hairless rat. J Pharm Pharmacol 2000;52:1437-1449.
41. Ohmori S, Sugiyama Y, Morimoto Y. A protective effect against undesirable increase of dihydroetorphine permeation through damaged skin by using pressure-sensitive adhesive tape with an ethylene-vinyl acetate co-polymer membrane. Biol Pharm Bull 2001;24:78-83.
42. Poter J, Jick H. Addiction rare in patients treated with narcotics. N Engl J Med 1980;302:123.
43. Qin BY. Reserch advances of dihydroetorphine: From analgesia to detoxification. New Drugs Clin Rem 1993;2:119-123.
44. th Edition. New York: MaGraw-Hill, 1996;521-555.
45. Shen KF, Crain SM. Antagonists and excitatory opioid receptors on sensory neurons in culture increase potency and specificity of opiate analgesics and attenuate development of tolerance/dependence. Brain Res 1994;636:286-297.
46. Shippenberg TS, Bals-Kubik R, Herz A. Examination of the neurochemical substrates mediating the motivational effects of opioids: Role of the mesolimbic dopamine system and D-1 vs D-2 dopamine receptors. J Pharmacol Exp Ther 1993;265:53-59.
47. Southam MA. Transdermal fentanyl therapy: System design, pharmacokinetics and efficacy. Anticancer Drugs 1995;(Suppl 3):29-34.
48. Stinchcomb A, Paliwal A, Dua R, Imoto H, Woodard RW, Flynn GL. Permeation of buprenorphine and its 3-alkyl-ester prodrugs through human skin. Pharm Res 1996; 13: 1519-1523.
49. Sugibayashi K, Sakanoue C, Morimoto Y. Utility of topical formulations of morphine hydrochloride containing azone and N-methyl-2-pyrrolidone. Sel Cancer Ther 1989;5:119-128.
50. Suzuki T, Kato H, Tsuda M, Suzuki H, Misawa M. Effects of the non-competitive NMDA receptor antagonist ifenprodil on the morphine-induced place preference in mice. Life Sci 1999;12:PL151-156.
51. Suzuki T, Kishimoto Y, Misawa M. Formalin- and carrageenan-induced inflamation attenuates place preferences produced by morphine, methamphetamine and cocaine. Life Sci 1996;59:1667-1674.
52. Suzuki T, Kishimoto Y, Misawa M, Nagase H, Takeda F. Role of the κ-opioid system in the attenuation of the morphine-induced place preference under chronic pain. Life Sci 1999;64:PL1-7.
53. Tokuyama S, Nakamura F, Takahashi M, Kaneto H. Physical dependence produced by dihydroetorphine in mice. Biol Pharm Bull 1994;17:1056-1059.
54. Tokuyama S, Nakamura F, Takahashi M, Kaneto H. Antinociceptive effect of dihydroetorphine following various routes of administration: A comparative study with morphine. Biol Pharm Bull 1996;19:477-479.
55. Tokuyama S, Takahashi M, Kaneto H. Antinociceptive effect of dihydroetorphine and its tolerance/dependence liability in mice. Biol Pharm Bull 1993;16:774-777.
56. Tzschentke TM. Measuring reward with the conditioned place preference paradigm: A comprehensive review of drug effects, recent progress and new issues. Progr Neurobiol 1998;56:613-672.
57. UN document. Commission on Narcotic Drugs, Report on the forty-second session. 1999; E/CN.7/1999/15/Rev. 1.
58. Vaccarino AL, Couret Jr. LC. Formalin-induced pain antagonizes the development of opiate dependence in the rat. Neurosci Lett 1993;161:195-198.
59. Vaccarino AL, Marek P, Kest B, et al. Morphine fails to produce tolerance when administered in the presence of formalin pain in rats. Brain Res 1993;627:287-290.
60. Wang CY, Li H, Cheng NS, Zhong JH, Wang B. An investigation on the situation of utilization of narcotic medications for cancer pain patients. Chin J Drug Depend 1999;8:210-213.
61. Wang DX, Liu YS, Qin BY. Experimental treatment of dihydroetorphine and naloxone on morphine-dependent rats and monkeys. Chin J Pharmacol Toxicol 1992;6:36-40.
62. Wang DX, Lu XQ, Qin BY. Dihydroetorphine is a μ-receptor-selective ligand. J Pharm Pharmacol 1995;47: 669-673.
63. 3H]dihydroetorphine to opioid receptors in rat brain membrane. Acta Pharmacol Sinica 1996;17:281-283.
64. Wang DX, Qin BY. Effect of dihydroetorphine treatment on regulation of μ-opioid receptor mRNA level in rat brain regions. Chin J Pharmacol Toxicol 1996;11:247-250.
65. Wang WP, Wang GL, Ha Y, Zheng JW. Psychological dependence potential of dihydroetorphine in rhesus monkey. Chin Bull Drug Depend 1997;6:8-12.
66. Wang SF, Yan DK, Yang Z, Qin BY, Wei YJ, Li FY. Clinical investigation on detoxification of heroin addiction with dihydroetorphine hydrochloride. Chin J Clin Pharmacol 1992;8:106-112.
67. Wang AP, Zhang QG, Huang CQ. Effect of dihydroetorphine hydrochrolide on mice parturition. Chin J Obstet Gynecol 1996;31:299-301.
68. Weber RJ, Pert A. The periaqueductal gray matter mediates opiate-induced immunosuppression. Science 1989;245:188-190.
69. WHO Expert Committee on Drug Dependence, Thirty-first Report. WHO Technical Report Series 887. Geneva: World Health Organization, 1999.
70. Wu GQ, Sun Y. Dihydroetorphine hydrochloride for moderate and severe cancer pain. Chin J Oncol 1991; 13:64-67.
71. Wu WR, Zheng JW, Li N, Bai HQ, Zhang KR, Li Y. Immunosuppressive effects of dihydroetorphine, a potent narcotic analgesic, in dihydroetorphine-dependent mice. Eur J Pharmacol 1999;366:261-269.
72. Wu WR, Zheng JW, Li FY, Li Y. Immunosuppresive effects of intravenous self administration of dihydroetorphine on lymphocyte functions in rats. Acta Pharmacol Sinica 1998;19:387-390.
73. Wu WR, Zheng JW, Li FY, Li Y, Zhang KR, Bai HQ. Involvement of μ-opioid receptors and α-adrenoceptors in the imunomodulatory effects of dihydroetorphine. Eur J Pharmacol 1998;353:79-85.
74. Yin H, Duan JJ, Li XQ. The effect of dihydroetorphine on neurobehavioral teratology in offsprings of mice. Chin Bull Drug Depend 1996;5:145-150.
75. Yu YK, Zhang L, Yin XX, Sun H, Uhl GR, Wang JB. μ-Opioid receptor phosphorylation, desensitization and ligand efficacy. J Biol Chem 1997;272:28869-28874.
76. 3H]-dihydroetorphine in mice. Acad Military Med Sci 1987;11:46-50.
77. 3H]-dihydroetorphine in rat brain observed by in vitro quantitative autoradiography. Chin J Pharmacol Toxicol 1995;9:61-64.
78. Zang DL. A survey on the utilization of narcotic analgesic drugs in general hospitals of Qingdao. Chin J Drug Depend 1999;8:204-206.
79. Zhang YG, Qin BY. Physical dependence of dihydroetorphine produced by continuous intraveous infusion in rats. Chin Bull Drug Depend 1994;3:218-222.